Whatever my colleague Mr. Davies may think, it's not necessary to have such a Manichaean vision of things. There are people who are trying to find solutions and areas of agreement. If the reform is adopted, the pharmaceutical companies won't even need to blackmail anyone; they can simply up stakes and quietly move elsewhere. We are living in a global context where competition is rather fierce.
That said, Mr. Chair, I'd like to propose the following motion:
That, pursuant to the motion adopted by the Committee on October 26, 2020 regarding the Patented Medicine Prices Review Board's (PMPRB) Guidelines Study, the Committee takes the following actions regarding the writing of the draft report: That a first drafted version of the report be sent to the members of the Committee; That, within two days following the adoption of this motion, all recognized parties recognized at the Committee send the recommendations it wishes to include into the report; That an additional hour be added to the June 18 meeting and that it be devoted to the study of the report and its adoption; That the deadline for tabling supplementary or dissenting opinions with the Clerk be set at 6:00 pm, two sitting days following the adoption of the report; That the Chair, Clerk and Analysts be authorized to make any necessary grammatical and editorial changes without changing the substance of the report, that the Chair or Vice-Chair be authorized to table the report in the House of Commons no later than June 22, 2021, and that the government provide a response to its results within 30 days That without altering the previously agreed upon calendar, and recognizing that committee resources are limited, that everything be done to have this report tabled by the date listed above.